Geneos Wealth Management Inc. Boosts Stake in Danaher Corporation $DHR

Geneos Wealth Management Inc. raised its holdings in Danaher Corporation (NYSE:DHR) by 9.3% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,271 shares of the conglomerate’s stock after buying an additional 1,558 shares during the period. Geneos Wealth Management Inc.’s holdings in Danaher were worth $3,746,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Intech Investment Management LLC boosted its position in Danaher by 46.8% in the 1st quarter. Intech Investment Management LLC now owns 14,591 shares of the conglomerate’s stock valued at $2,991,000 after buying an additional 4,653 shares during the period. Focus Partners Wealth lifted its position in shares of Danaher by 10.7% during the 1st quarter. Focus Partners Wealth now owns 196,682 shares of the conglomerate’s stock worth $40,328,000 after purchasing an additional 19,086 shares during the last quarter. Flaharty Asset Management LLC purchased a new stake in shares of Danaher during the 1st quarter worth $88,000. Integrity Alliance LLC. raised its stake in Danaher by 191.4% during the 1st quarter. Integrity Alliance LLC. now owns 4,831 shares of the conglomerate’s stock worth $990,000 after acquiring an additional 3,173 shares in the last quarter. Finally, Ransom Advisory Ltd acquired a new stake in Danaher during the 1st quarter worth $536,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the business’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 11.10% of the stock is currently owned by company insiders.

Danaher Trading Down 0.8%

NYSE DHR opened at $192.85 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The firm has a market cap of $138.09 billion, a PE ratio of 41.03, a P/E/G ratio of 2.71 and a beta of 0.75. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90. The firm’s fifty day moving average is $201.62 and its two-hundred day moving average is $199.15.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. Danaher’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher’s payout ratio is 27.23%.

Analysts Set New Price Targets

DHR has been the topic of several research analyst reports. UBS Group cut their price target on shares of Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, July 23rd. Wells Fargo & Company cut their price target on shares of Danaher from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft cut their price target on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Scotiabank upgraded shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price target on the stock in a research note on Friday, July 11th. Finally, Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a research note on Tuesday, September 2nd. Seventeen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $246.35.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.